SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 3

Suicide Attempt with High Dose Long Acting Methylphenidate Ingestion: A Case Presentation

Handan Özek ERKURAN
Burcu CAKALOZ
Ozlem ONEN
Ayse KUTLU
Pages
316–318
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case report might suggest that higher doses of MPH-OROS could be tolerated well under fine clinical observation and management; although more larger scale studies in this field would be required

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Attention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%.
📊
Key Findings & Data:Among the recommended treatment regimens as stimulants, the most frequently advised ones are methylphenidate (MPH) preparates.
💡
Conclusion & Impact:This case report might suggest that higher doses of MPH-OROS could be tolerated well under fine clinical observation and management; although more larger scale studies in this field would be required
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Attention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the recommended treatment regimens as stimulants, the most frequently advised ones are methylphenidate (MPH) preparates. Among long acting MPH preparates, the form that contains an osmotic release oral system (MPH-OROS) is frequently used in clinical practice. Studies about risks, causes and outcomes regarding high dose MPH intake and effects of high dose MPH preparates in humans are limited. This article presents the clinical picture of a 12 year old boy who attempted suicide by ingesting 15 tablets of 36- mg MPH OROS. Exposure to an overdose of MPH-OROS exhibited acute sympathomimetic toxicity but no life-threatening symptoms in this patient. This case report might suggest that higher doses of MPH-OROS could be tolerated well under fine clinical observation and management; although more larger scale studies in this field would be required

🔖

Cite This Article

ERKURAN, H. Ö., CAKALOZ, B., ONEN, O., KUTLU, A. (2022). Suicide Attempt with High Dose Long Acting Methylphenidate Ingestion: A Case Presentation. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 3, 316–318. https://ajindex.com/articles/573919

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164(6):942-8. [CrossRef] 2. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921. [CrossRef] 3. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60(2):204-11. [CrossRef] 4. Katzman MA, Sternat T. A Review of OROS methylphenidate (Concerta®) in the treatment of attention-deficit/hyperactivity disorder. CNS Drugs 201;28(11):1005-33. [CrossRef] 5. White SR, Yadao CM. Characterization of methylphenidate exposures reported to a regional poison control centre. Arch Pediatr Adolesc Med 2000;154(12):1199-203. [CrossRef] 6. Klampfl K, Quattländer A, Burger R, Pfuhlmann B, Warnke A, Gerlach M. Case report: intoxication with high dose of long-acting methylphenidate (Concerta®) in a suicidal 14-year-old girl. Atten Defic Hyperact Disord 2010;2(4):221-4. [CrossRef] 7. Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM. et al. American Association of Poison Control Centers. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45(7):737-52. [CrossRef] 8. Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013;27(7):531-43. [CrossRef] 9. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002;14(2): 219-23. [CrossRef] 10. Eryilmaz G, Gul IG, Yorbik O, Isiten N. Long-acting methylphenidate toxicity: a case report. Klinik Psikofarmakoloji Bulteni- Bulletin of Clinical Psychopharmacology 2014;24(4):384-6. [CrossRef] 11. Ozdemir E, Karaman MG, Yurteri N, Erdogan A. A case of suicide attempt with long-acting methylphenidate (Concerta). Atten Defic Hyperact Disord 2010;2(3):103-5. [CrossRef]